News
Novartis’ Fabhalta Receives Traditional FDA Approval for IgA Nephropathy
Novartis is helping improve access to Fabhalta for patients with primary immunoglobulin A nephropathy (IgAN) through a variety of support programmes.
imphoenix82
- July 17, 2026
- 0 Comments
- 49 Views
-
